CD19 and neoplasm: Over the course of our analysis of the M-MDCSs, defined as CD45+ LINneg (CD3, CD56, CD19) CD11b+CD33+CD14+HLA-DRdim/neg, in pts with CRC, we observed a significant increase in CD15+ monocytes in both the PB and tumor tissue (Figure 1A).